O

OS Therapies Inc
AMEX:OSTX

Watchlist Manager
OS Therapies Inc
AMEX:OSTX
Watchlist
Price: 3.83 USD -3.53% Market Closed
Market Cap: 53.3m USD
Have any thoughts about
OS Therapies Inc?
Write Note

OS Therapies Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

OS Therapies Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
O
OS Therapies Inc
AMEX:OSTX
Current Portion of Long-Term Debt
$14.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Current Portion of Long-Term Debt
$12.6B
CAGR 3-Years
24%
CAGR 5-Years
19%
CAGR 10-Years
89%
Gilead Sciences Inc
NASDAQ:GILD
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Current Portion of Long-Term Debt
$3.5B
CAGR 3-Years
-6%
CAGR 5-Years
12%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

OS Therapies Inc
Glance View

Market Cap
53.3m USD
Industry
Biotechnology

OS Therapies Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. OS Therapies Incorporated is a clinical-stage biopharmaceutical company. The firm is focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company built a pipeline of product candidates targeting multiple indications for solid cancers. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. OST-HER2 is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH sensitive silicone linkers (SiLinkers). The payloads can include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments directly into and in the vicinity of solid tumors.

OSTX Intrinsic Value
4.19 USD
Undervaluation 9%
Intrinsic Value
Price
O

See Also

What is OS Therapies Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
14.6m USD

Based on the financial report for Dec 31, 2023, OS Therapies Inc's Current Portion of Long-Term Debt amounts to 14.6m USD.

Back to Top